Compare iShares Global Clean Energy ETF (ICLN) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Pfizer Inc — how do they compare? iShares Global Clean Energy ETF trades at $17.28 (market cap $2.30B), while Pfizer Inc trades at $27.78 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 69.4× iShares Global Clean Energy ETF's market cap, and Pfizer Inc pays a 6.14% dividend while iShares Global Clean Energy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 87 Days and Pfizer Inc for 158 Days on average.
| ICLN | PFE | |
|---|---|---|
Market Cap | $2.30B | $159.59B |
Volume | 3,661,617 | 30,937,010 |
52-Week High | $23.75 | $29.02 |
52-Week Low | $15.78 | $23.67 |
Typical Hold Time | 87 Days | 158 Days |
Sector | — | Health |
Enterprise Value | — | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.31, down 1.31% with a bearish technical signal from moving averages. The ETF faces volatility with clean energy exposure showing deeper drawdowns compared to traditional energy peers. Recent news highlights competitive pressure from fossil fuel ETFs delivering stronger returns and lower fees, though geopolitical tensions are accelerating global renewable energy adoption.
The outlook remains challenged by high expense ratios and sector volatility, but long-term growth potential exists from global energy transition trends. Key risks include competitive pressure from traditional energy and execution challenges in renewable adoption timelines.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
